Gene Editing: CRISPR-Cas9, Indian SDN Rules & Sickle Cell Mission

UPSC Mains PYQs

CRISPR & Gene Editing (2019): "What is CRISPR-Cas9 technology and how can it be used to treat genetic disorders?" Discuss the ethical and regulatory challenges associated with gene editing in humans, with a special emphasis on somatic versus germline editing. (15 Marks, 250 Words)

📊 High-Yield Data & Statistical Fact Sheet

Gene Editing & Disease Metrics:
- Sickle Cell Elimination: National Mission targets elimination by 2047, aiming to screen 7.0 Crore tribal citizens under 40 years across 17 high-burden states.
- Socioeconomic Burden: India has the second-highest global burden of Sickle Cell Disease (approx. 1 in 86 births in tribal tracts).
- CRISPR Nobel: chemistry prize awarded in 2020 to Emmanuelle Charpentier and Jennifer A. Doudna.
- Monopoly Pricing: Commercial therapies like FDA-approved Casgevy cost $2.2 Million (~₹18 Crore) per patient, necessitating India's indigenous BIRSA-101 somatic therapy.
- Off-Target Ratios: Standard CRISPR platforms have an off-target cut rate of 1% to 5%, whereas base and prime editing slash this under 0.1%.
- Agriculture Easing: DBT has exempted SDN-1 and SDN-2 categories of edited plants from biosafety trials, cutting commercial release timelines.

Loading chart...

Loading chart...

1. CRISPR-CAS9 AND INDIAN MINI-SCISSORS (BIRSA-101)

CRISPR-Cas9 Mechanics: Clustered Regularly Interspaced Short Palindromic Repeats. Derived from bacterial immune systems. Comprises two key components:
- Guide RNA (gRNA): A synthetic RNA sequence designed to locate and bind to a specific target DNA sequence.
- Cas9 Endonuclease: The molecular scalpel that creates a double-stranded break at the targeted locus.
BIRSA-101 Somatic Therapy: India's premier indigenous CRISPR-based clinical somatic gene therapy designed to treat sickle cell anemia and beta-thalassemia at a fraction of Western costs.
TnpB Miniature Scissors: A patented extremophilic bacterial protein. Only one-third the size of Cas9, allowing easy delivery into target tissues using non-toxic viral vectors.

DBT SDN Guidelines (2022): Establishes a tiered biosafety roadmap based on Site-Directed Nuclease (SDN) modifications:
- SDN-1: Introduces site-directed double-strand breaks without donor DNA. Excised and repaired via natural non-homologous end-joining. Exempted from GEAC clearance.
- SDN-2: Uses a small template to repair and edit specific nucleotides. No foreign DNA integrated. Exempted from GEAC clearance.
- SDN-3: Inserts a large, foreign transgene. Classed as a traditional Genetically Modified (GM) crop. Requires full GEAC regulatory clearances.
Impact on Crop Breeding: SDN-1 & SDN-2 exemptions bypass multi-year transgenic field trials, shortening crop development cycles from 12 years to 3-5 years.

Monopoly Pricing Barriers: FDA-approved CRISPR therapeutics like Casgevy cost upward of $2.2 Million (₹18 Crore). This makes local, state-supported molecular research (such as BIRSA-101) essential for public health access.
The Germline Red-line:
- Somatic Editing: Alters non-inheritable tissues (e.g., bone marrow) to cure a living patient. Widely approved.
- Germline Editing: Alters sperm, egg, or early embryos. Changes are inheritable across generations. Globally banned due to risk of introducing permanent mutations, off-target cuts, and eugenics ("designer babies").
Off-Target Mutations: Unintended DNA cutting at off-target genomic sites, which can damage vital genes and potentially trigger malignancies.

Notes updated up to March 2026. Sources: DBT Genome Editing Guidelines, Ministry of Health Mission Documents.